A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk.
Aged
Cardiovascular Diseases
/ prevention & control
Diet, Fat-Restricted
Diet, Mediterranean
Female
Humans
Liver
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ diagnostic imaging
Nuts
Olive Oil
/ administration & dosage
Prevalence
Primary Prevention
Risk Factors
Spain
/ epidemiology
Mediterranean diet
PREDIMED
dietary fat
hepatic steatosis
nuts
olive oil
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
02
11
2018
revised:
30
11
2018
accepted:
04
06
2019
pubmed:
25
7
2019
medline:
27
6
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
Adherence to a Mediterranean diet (MedDiet) is thought to reduce liver steatosis. To explore the associations with liver steatosis of 3 different diets: a MedDiet + extra-virgin olive oil (EVOO), MedDiet + nuts, or a control diet. This was a subgroup analysis nested within a multicenter, randomized, parallel-group clinical trial, PREvención con DIeta MEDiterránea (PREDIMED trial: ISRCTN35739639), aimed at assessing the effect of a MedDiet on the primary prevention of cardiovascular disease. One hundred men and women (mean age: 64 ± 6 y), at high cardiovascular risk (62% with type 2 diabetes) from the Bellvitge-PREDIMED center were randomly assigned to a MedDiet supplemented with EVOO, a MedDiet supplemented with mixed nuts, or a control diet (advice to reduce all dietary fat). No recommendations to lose weight or increase physical activity were given. Main measurements were the percentage of liver fat and the diagnosis of steatosis, which were determined by NMR imaging. The association of diet with liver fat content was analyzed by bivariate analysis after a median follow-up of 3 y. Baseline adiposity and cardiometabolic risk factors were similar among the 3 treatment arms. At 3 y after the intervention hepatic steatosis was present in 3 (8.8%), 12 (33.3%), and 10 (33.3%) of the participants in the MedDiet + EVOO, MedDiet + nuts, and control diet groups, respectively (P = 0.027). Respective mean values of liver fat content were 1.2%, 2.7%, and 4.1% (P = 0.07). A tendency toward significance was observed for the MedDiet + EVOO group compared with the control group. Median values of urinary 12(S)-hydroxyeicosatetraenoic acid/creatinine concentrations were significantly (P = 0.001) lower in the MedDiet + EVOO (2.3 ng/mg) than in the MedDiet + nuts (5.0 ng/mg) and control (3.9 ng/mg) groups. No differences in adiposity or glycemic control changes were seen between groups. An energy-unrestricted MedDiet supplemented with EVOO, a food with potent antioxidant and anti-inflammatory properties, is associated with a reduced prevalence of hepatic steatosis in older individuals at high cardiovascular risk.
Sections du résumé
BACKGROUND
Adherence to a Mediterranean diet (MedDiet) is thought to reduce liver steatosis.
OBJECTIVES
To explore the associations with liver steatosis of 3 different diets: a MedDiet + extra-virgin olive oil (EVOO), MedDiet + nuts, or a control diet.
METHODS
This was a subgroup analysis nested within a multicenter, randomized, parallel-group clinical trial, PREvención con DIeta MEDiterránea (PREDIMED trial: ISRCTN35739639), aimed at assessing the effect of a MedDiet on the primary prevention of cardiovascular disease. One hundred men and women (mean age: 64 ± 6 y), at high cardiovascular risk (62% with type 2 diabetes) from the Bellvitge-PREDIMED center were randomly assigned to a MedDiet supplemented with EVOO, a MedDiet supplemented with mixed nuts, or a control diet (advice to reduce all dietary fat). No recommendations to lose weight or increase physical activity were given. Main measurements were the percentage of liver fat and the diagnosis of steatosis, which were determined by NMR imaging. The association of diet with liver fat content was analyzed by bivariate analysis after a median follow-up of 3 y.
RESULTS
Baseline adiposity and cardiometabolic risk factors were similar among the 3 treatment arms. At 3 y after the intervention hepatic steatosis was present in 3 (8.8%), 12 (33.3%), and 10 (33.3%) of the participants in the MedDiet + EVOO, MedDiet + nuts, and control diet groups, respectively (P = 0.027). Respective mean values of liver fat content were 1.2%, 2.7%, and 4.1% (P = 0.07). A tendency toward significance was observed for the MedDiet + EVOO group compared with the control group. Median values of urinary 12(S)-hydroxyeicosatetraenoic acid/creatinine concentrations were significantly (P = 0.001) lower in the MedDiet + EVOO (2.3 ng/mg) than in the MedDiet + nuts (5.0 ng/mg) and control (3.9 ng/mg) groups. No differences in adiposity or glycemic control changes were seen between groups.
CONCLUSIONS
An energy-unrestricted MedDiet supplemented with EVOO, a food with potent antioxidant and anti-inflammatory properties, is associated with a reduced prevalence of hepatic steatosis in older individuals at high cardiovascular risk.
Identifiants
pubmed: 31334554
pii: S0022-3166(22)16478-3
doi: 10.1093/jn/nxz147
doi:
Substances chimiques
Olive Oil
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1920-1929Investigateurs
R Estruch
(R)
M A Martínez-González
(MA)
D Corella
(D)
M Fitó
(M)
E Ros
(E)
J Salas-Salvadó
(J)
F Arós
(F)
M Aldamiz-Echevarría
(M)
A M Alonso-Gómez
(AM)
J Berjón
(J)
L Forga
(L)
J Gállego
(J)
A García-Layana
(A)
A Larrauri
(A)
J Portu-Zapirain
(J)
J Timiraos
(J)
E Ros
(E)
M I Covas
(MI)
M A Martínez-González
(MA)
J Salas-Salvadó
(J)
A Pérez-Heras
(A)
M Serra-Mir
(M)
X Pi-Sunyer
(X)
C A González
(CA)
F B Hu
(FB)
J Sabaté
(J)
E de la Cruz
(E)
A Galera
(A)
M Gimenez-Garcia
(M)
H Lafuente
(H)
M A Rodríguez-Sanchez
(MA)
F Trias
(F)
I Sarasa
(I)
R Figueras
(R)
M Liceran
(M)
C Pallarols
(C)
V Esteve
(V)
C Storniolo
(C)
M Serra-Mir
(M)
A Pérez-Heras
(A)
A Sala-Vila
(A)
C Valls-Pedret
(C)
C Viñas
(C)
R Casas
(R)
A Medina-Remón
(A)
S Romero
(S)
J M Baena
(JM)
M García
(M)
M Oller
(M)
J Amat
(J)
I Duaso
(I)
Y García
(Y)
C Iglesias
(C)
C Simón
(C)
L Quinzavos
(L)
L Parra
(L)
M Liroz
(M)
J Benavent
(J)
J Clos
(J)
I Pla
(I)
M Amorós
(M)
M T Bonet
(MT)
M T Martín
(MT)
M S Sánchez
(MS)
J Altirriba
(J)
E Manzano
(E)
A Altés
(A)
M Cofán
(M)
M Doménech
(M)
T M Freitas-Simoes
(TM)
I Roth
(I)
A J Amor
(AJ)
E Ortega
(E)
J C Laguna
(JC)
M Alegret
(M)
R Gilabert
(R)
N Bargalló
(N)
M A Martínez-González
(MA)
P Buil-Cosiales
(P)
E Toledo
(E)
A García-Arellano
(A)
J C Cenoz-Osinaga
(JC)
O Lecea-Juárez
(O)
C Razquin
(C)
A Sánchez-Tainta
(A)
B Sanjulián
(B)
J Díez-Espino
(J)
I Zazpe
(I)
F J Basterra-Gortari
(FJ)
S Eguaras
(S)
E Goñi
(E)
Z Vazquez
(Z)
M Bes-Rastrollo
(M)
A Gea
(A)
N Martín-Calvo
(N)
N Berrade
(N)
A Marti
(A)
J Alfredo Martínez
(J)
E H Martínez-Lapiscina
(EH)
M García-López
(M)
S Cervantes
(S)
F Barcena Amigo
(F)
C Oreja Arrayago
(C)
M J Lasanta Saez
(MJ)
L Quintana Pedraza
(L)
P Cia Lecumberri
(P)
T Elcarte Lopez
(T)
T Forcen Alonso
(T)
I Alvárez-Alvárez
(I)
J Salas-Salvadó
(J)
M Guasch-Ferré
(M)
R González
(R)
C Molina
(C)
F Márquez
(F)
N Babio
(N)
J García Roselló
(J)
A Diaz-López
(A)
F Martin
(F)
R Tort
(R)
A Isach
(A)
N Becerra
(N)
C Ferreira
(C)
J J Cabré
(JJ)
J Fernández-Ballart
(J)
N Ibarrola-Jurado
(N)
G Mestres
(G)
N Rosique-Esteban
(N)
C Alegret
(C)
P Martínez
(P)
S Millán
(S)
J L Piñol
(JL)
T Basora
(T)
A Salas-Huetos
(A)
J M Hernández
(JM)
P Carrasco
(P)
C Ortega-Azorín
(C)
E M Asensio
(EM)
R Osma
(R)
R Barragán
(R)
F Francés
(F)
M Guillén
(M)
J I González
(JI)
C Sáiz
(C)
O Portolés
(O)
F J Giménez
(FJ)
O Coltell
(O)
R Fernández-Carrión
(R)
P Guillem-Sáiz
(P)
I González-Monje
(I)
L Quiles
(L)
V Pascual
(V)
C Riera
(C)
M A Pages
(MA)
D Godoy
(D)
A Carratalá-Calvo
(A)
S Sánchez-Navarro
(S)
C Valero-Barceló
(C)
M Fitó
(M)
J Vila
(J)
I Subirana
(I)
S Tello
(S)
R de la Torre
(R)
D Muñoz-Aguayo
(D)
R Elosua
(R)
J Marrugat
(J)
H Schröder
(H)
N Molina
(N)
E Maestre
(E)
A Rovira
(A)
M Farré
(M)
F Arós
(F)
J Timiraos
(J)
I Salaverría
(I)
J Rekondo
(J)
M C Belló
(MC)
T Del Hierro
(T)
J Algorta
(J)
S Francisco
(S)
A Alonso
(A)
J San Vicente
(J)
E Sanz
(E)
I Felipe
(I)
A Alonso Gómez
(A)
A Loma-Osorio
(A)
E Gómez-Gracia
(E)
J Fernández-Crehuet
(J)
M Gutiérrez-Bedmar
(M)
R Benítez Pont
(R)
M Bianchi Alba
(M)
J Wärnberg
(J)
R Gómez-Huelgas
(R)
J Martínez-González
(J)
V Velasco García
(V)
J de Diego Salas
(J)
A Baca Osorio
(A)
J Gil Zarzosa
(J)
J J Sánchez Luque
(JJ)
E Vargas López
(E)
D Romaguera
(D)
M García-Valdueza
(M)
M Moñino
(M)
A Yáñez
(A)
A Proenza
(A)
R Prieto
(R)
S Munuera
(S)
M Vivó
(M)
F Bestard
(F)
J A Munar
(JA)
L Coll
(L)
F Fiol
(F)
M Ginard
(M)
A Jover
(A)
J García
(J)
M Leal
(M)
E Martínez
(E)
J M Santos-Lozano
(JM)
M Ortega-Calvo
(M)
P Román
(P)
F José García
(F)
P Iglesias
(P)
Y Corchado
(Y)
L Mellado
(L)
L Miró-Moriano
(L)
J M Lozano-Rodríguez
(JM)
C Domínguez-Espinaco
(C)
S Vaquero-Díaz
(S)
M C López-Sabater
(MC)
A I Castellote-Bargalló
(AI)
P Quifer-Rada
(P)
Las Palmas
(L)
J Álvarez-Pérez
(J)
E M Díaz-Benítez
(EM)
A Sánchez-Villegas
(A)
L T Casañas-Quintana
(LT)
J Pérez-Cabrera
(J)
C Ruano-Rodríguez
(C)
I Bautista-Castaño
(I)
F Sarmiento de la Fe
(F)
J A García Pastor
(JA)
B V Díaz-González
(BV)
J M Castillo Anzalas
(JM)
R E Sosa-Also
(RE)
J Medina-Ponce
(J)
C Cabezas
(C)
E Vinyoles
(E)
M A Rovira
(MA)
L García
(L)
G Flores
(G)
J M Verdú
(JM)
P Baby
(P)
A Ramos
(A)
L Mengual
(L)
P Roura
(P)
M C Yuste
(MC)
A Guarner
(A)
A Rovira
(A)
M I Santamaría
(MI)
M Mata
(M)
C de Juan
(C)
A Brau
(A)
V Ruiz-Gutiérrez
(V)
J Sánchez Perona
(J)
E Montero Romero
(E)
M García-García
(M)
E Jurado-Ruiz
(E)
M P Portillo
(MP)
G Sáez
(G)
J Tur
(J)
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © American Society for Nutrition 2019.